OncoMatch/Clinical Trials/NCT03548571
Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
Is NCT03548571 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Dendritic cell immunization and Adjuvant temozolomide for glioblastoma.
Treatment: Dendritic cell immunization · Adjuvant temozolomide — Open, randomized study of a trivalent dendritic cell therapy compared to standard therapy in primary treated patients with IDH wild-type, MGMT-promotor methylated glioblastoma. The IMP is dendritic cells transfected with mRNA of survivin, hTERT og autologous tumor stem cells derived from tumorspheres.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: MGMT unmethylated promoter
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy or other potentially immune-suppressive therapy
Exception: outside protocol; within the last 4 weeks prior to vaccination
Chemotherapy or other potentially immune-suppressive therapy outside protocol that has been administered within the last 4 weeks prior to vaccination
Cannot have received: splenectomy
Prior splenectomy
Lab requirements
Blood counts
ANC > 1.5 x 10^9/L; platelets >100 x10^9/L, Hb >9g/dL (> 5.6 mmol/L)
Kidney function
Creatinine < 140 µmol/L (1.6 mg/dL); if borderline, the creatinine clearance >40 mL/min
Liver function
Bilirubin < 20% above the upper limit of normal, ASAT and ALAT < 2.5 the upper limit of normal, Albumin >2.5 g/L
Normal organ function defined by laboratory values as following: ANC > 1.5 x 10^9/L; platelets >100 x10^9/L, Hb >9g/dL (> 5.6 mmol/L). Creatinine < 140 µmol/L (1.6 mg/dL); if borderline, the creatinine clearance >40 mL/min, Bilirubin < 20% above the upper limit of normal, ASAT and ALAT < 2.5 the upper limit of normal. Albumin >2.5 g/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify